Edwards Lifesciences Corp (NYSE:EW) has been assigned an average recommendation of “Buy” from the twenty-two ratings firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $167.89.
A number of research analysts have recently weighed in on EW shares. Barclays started coverage on Edwards Lifesciences in a research report on Monday, October 15th. They set an “underweight” rating and a $143.00 price objective on the stock. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $180.00 to $190.00 in a research report on Friday, January 18th. Deutsche Bank initiated coverage on Edwards Lifesciences in a research report on Wednesday, January 2nd. They set a “hold” rating and a $164.00 price objective on the stock. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price on shares of Edwards Lifesciences in a research note on Sunday, February 3rd. Finally, Zacks Investment Research downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 25th.
Shares of EW stock traded up $1.68 during trading hours on Friday, reaching $171.93. 894,628 shares of the company traded hands, compared to its average volume of 1,363,494. Edwards Lifesciences has a 12-month low of $121.40 and a 12-month high of $175.00. The company has a quick ratio of 1.92, a current ratio of 2.61 and a debt-to-equity ratio of 0.19. The stock has a market cap of $35.59 billion, a P/E ratio of 36.58, a PEG ratio of 2.20 and a beta of 0.92.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.17. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. The firm had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. During the same period in the previous year, the firm earned $0.94 EPS. On average, equities research analysts expect that Edwards Lifesciences will post 5.22 earnings per share for the current fiscal year.
In other Edwards Lifesciences news, VP Larry L. Wood sold 6,300 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $147.96, for a total value of $932,148.00. Following the sale, the vice president now owns 25,490 shares of the company’s stock, valued at approximately $3,771,500.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $150.88, for a total value of $4,963,952.00. Following the completion of the sale, the chief executive officer now directly owns 76,026 shares in the company, valued at approximately $11,470,802.88. The disclosure for this sale can be found here. Insiders have sold a total of 161,288 shares of company stock worth $24,202,388 in the last three months. 1.84% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in EW. FMR LLC boosted its holdings in shares of Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock worth $977,456,000 after purchasing an additional 1,663,511 shares during the period. Advisors Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences by 25.8% in the 2nd quarter. Advisors Asset Management Inc. now owns 27,880 shares of the medical research company’s stock worth $4,058,000 after purchasing an additional 5,725 shares during the period. LFA Lugano Financial Advisors SA purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $121,000. Wendell David Associates Inc. boosted its holdings in shares of Edwards Lifesciences by 4.9% in the 3rd quarter. Wendell David Associates Inc. now owns 10,015 shares of the medical research company’s stock worth $1,744,000 after purchasing an additional 467 shares during the period. Finally, Busey Trust CO purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $272,000. 82.41% of the stock is currently owned by institutional investors and hedge funds.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Read More: Buyback
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.